Supplemental Table 1 from Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

Rotow, Julia K.; Gui, Philippe; Wu, Wei; Raymond, Victoria M.; Lanman, Richard B.; Kaye, Frederic J.; Peled, Nir; Fece de la Cruz, Ferran; Nadres, Brandon; Corcoran, Ryan B.; Yeh, Iwei; Bastian, Boris C.; Starostik, Petr; Newsom, Kimberly; Olivas, Victor R.; Wolff, Alexander M.; Fraser, James S.; Collisson, Eric A.; McCoach, Caroline E.; Camidge, D. Ross; Pacheco, Jose; Bazhenova, Lyudmila; Li, Tianhong; Bivona, Trever G.; Blakely, Collin M.

doi:10.1158/1078-0432.22473410.v1

10780432ccr191667-sup-222690_2_supp_5717688_pwmyxm.docx (13.36 kB)

Supplemental Table 1 from Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

journal contribution

posted on 2023-03-31, 21:25 authored by Julia K. Rotow, Philippe Gui, Wei Wu, Victoria M. Raymond, Richard B. Lanman, Frederic J. Kaye, Nir Peled, Ferran Fece de la Cruz, Brandon Nadres, Ryan B. Corcoran, Iwei Yeh, Boris C. Bastian, Petr Starostik, Kimberly Newsom, Victor R. Olivas, Alexander M. Wolff, James S. Fraser, Eric A. Collisson, Caroline E. McCoach, D. Ross Camidge, Jose Pacheco, Lyudmila Bazhenova, Tianhong Li, Trever G. Bivona, Collin M. Blakely

Demographics of the METex14-mutated and EGFR-mutated cohorts.

Funding

NIH

NCI

History

ARTICLE ABSTRACT

Although patients with advanced-stage non–small cell lung cancers (NSCLC) harboring MET exon 14 skipping mutations (METex14) often benefit from MET tyrosine kinase inhibitor (TKI) treatment, clinical benefit is limited by primary and acquired drug resistance. The molecular basis for this resistance remains incompletely understood. Targeted sequencing analysis was performed on cell-free circulating tumor DNA obtained from 289 patients with advanced-stage METex14-mutated NSCLC. Prominent co-occurring RAS–MAPK pathway gene alterations (e.g., in KRAS, NF1) were detected in NSCLCs with METex14 skipping alterations as compared with EGFR-mutated NSCLCs. There was an association between decreased MET TKI treatment response and RAS–MAPK pathway co-occurring alterations. In a preclinical model expressing a canonical METex14 mutation, KRAS overexpression or NF1 downregulation hyperactivated MAPK signaling to promote MET TKI resistance. This resistance was overcome by cotreatment with crizotinib and the MEK inhibitor trametinib. Our study provides a genomic landscape of co-occurring alterations in advanced-stage METex14-mutated NSCLC and suggests a potential combination therapy strategy targeting MAPK pathway signaling to enhance clinical outcomes.

Usage metrics

Keywords

Drug Targets Hematological Cancers Liquid Biopsy Lung Cancer

Licence

CC BY

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Supplemental Table 1 from Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

Funding

NIH

NCI

History

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports